I need an Agreement

Industry Sponsored Research Agreements Overview

TTBD is responsible for assuring that the terms of Sponsored Research Agreements (SRAs) protect the investigator and the institution. This includes, but is not limited to, protecting the investigator's intellectual property, performing due diligence, and assuring that projects are within the scope of the University's mission.

The investigator is responsible for completing all necessary compliance, such as IRB, IACUC or IBC approval. Investigators must also provide a complete scope of work, budget and PPQ as well as disclosing any potential conflicts that may impact the terms of the agreement.

Learn More about SRAs, visit the SRA FAQ Page.

Current Industry Collaboration Opportunities

Eli Lilly OIDD Initiative

Eli Lilly has created the Open Innovation Drug Discovery Program as one mechanism to collaborate with academic institutes. The OIDD Program (previously known as the PD2 Initiative) provides a means for screening potentially therapeutic compounds developed at academic research centers in Lilly's proprietary assay system.

Lilly will screen compounds in a set of assay modules that include a primary phenotypic screening and secondary biochemical and cellular assays in the following areas:

  • Cancer
  • Bone Formation
  • Endocrine/Diabetes
  • Cardiovascular
  • Neuroscience
  • Rare and Neglected Diseases

The OIDD Screening Process:

1.       OHSU Researcher submits the compound's chemical structure in an electronic format to assess sufficient drug-like activity and structural novelty through the Lilly website. The information remains confidential and is screened by web-based rules, rather than Lilly employees.

2.       If the compound is selected, the OHSU researcher submits a small amount of selected compound in bar-coded vials at no cost. Compounds are submitted under a pre-signed master Material Transfer Agreement. All IP rights remain with the university.

3.       Lilly screens the compounds using their proprietary assay system

4.       Lilly provides a final report to the investigator and university

5.       After the screening results, Lilly may ask the university to enter in to a confidentiality agreement to disclose the chemical structure and establish a dialog for either further collaborative research or licensing.

There are no restrictions regarding the use of the Lilly report data. University researchers are free to publish and/or use the data in support of proposals to funding agencies. This service is provided for free to universities.

OHSU recently signed agreements giving our faculty access to this program. For more information or to submit your compounds, contact OHSU's office of Technology Transfer & Business Development.

Detailed information about Lilly's OIDD Program, and the science behind it, can be found on Lilly's website.